Iboga treats addiction by acting directly on the neurological substrate that sustains it. The mechanism operates through GDNF restoration, opioid receptor normalisation, and dopamine circuit interruption — in a way no current pharmaceutical treatment approaches. The evidence spans opioid, alcohol, and stimulant dependence. And a meaningful number of the people who most want this treatment are not medically eligible for it.
Iboga is the whole-plant root bark of Tabernanthe iboga, containing 30+ alkaloids. For addiction, it restores GDNF in the mesolimbic pathway, resets opioid receptor physiology, and interrupts the dopamine reward circuit that sustains craving. A single ceremony creates a neuroplasticity window lasting weeks to months. A 12-lead EKG, liver function panel, and full medication review are required before any ceremony date is confirmed.
What "Iboga" Means in This Context
The distinction between iboga and ibogaine matters specifically for addiction treatment.
Ibogaine is one alkaloid — the primary psychoactive compound extracted from the Tabernanthe iboga plant. It is what most clinical research has studied, and what most addiction-focused treatment centres administer: isolated ibogaine hydrochloride in capsule form, calculated by body weight.
Iboga is the whole plant. The root bark contains 30+ alkaloids in addition to ibogaine — including noribogaine (ibogaine's primary metabolite, already present in the root bark itself), tabernanthine, ibogaline, and others. Whether the whole-plant preparation produces meaningfully different results than isolated ibogaine is not definitively settled in the research. Practitioners who work with whole-plant consistently report a different character to the experience: longer integration of visual material, more gradual onset, more pronounced engagement with biographical content. The neurological basis for this is plausible — alkaloid combinations can act synergistically in ways isolated compounds do not.
At Transcend, we work with whole-plant root bark in the Bwiti tradition. The addiction-relevant mechanisms — GDNF restoration, opioid receptor reset, dopamine circuit interruption — are present in both preparations. The ceremonial context and preparation protocol differ substantially from clinical ibogaine HCl administration.
How Iboga Interrupts Addiction Neurologically
Addiction is not a discipline problem. It is a neurological condition — sustained by changes in the dopamine reward circuit, opioid receptor sensitivity, and neuroprotective protein levels that conventional treatment is largely unable to reverse.
Iboga acts on several of these simultaneously.
GDNF restoration. GDNF — glial cell line-derived neurotrophic factor — is a neuroprotective protein responsible for the survival of dopamine-producing neurons in the mesolimbic pathway. Chronic substance use depletes it. Research published in the Journal of Neuroscience documented that ibogaine restores GDNF to near-normal levels in the ventral tegmental area and striatum — the core of the reward circuit — and associated this restoration with 90%+ reductions in voluntary ethanol consumption in animal models, persisting for weeks after a single dose. No currently approved addiction treatment has demonstrated GDNF restoration at this level.
Opioid receptor normalisation. In substance-dependent individuals, the opioid receptor system adapts to the presence of the substance — down-regulating sensitivity during use or amplifying craving during abstinence. Ibogaine interacts with opioid receptors in a way that interrupts this adapted state. The effect is relevant not just for opioid dependence, but for alcohol use disorder — where endogenous opioid release is central to the reward mechanism — and for stimulant dependence, where overlapping dopamine pathways are implicated.
Dopamine circuit interruption. Ibogaine acts on multiple receptor systems simultaneously: opioid, NMDA, sigma-2, and serotonin transporters. This multi-target action during the active 12–24 hour experience creates a period in which established craving patterns are substantially disrupted. The consistent clinical observation — across addiction types — is that craving does not return at pre-ceremony intensity in the weeks immediately following. That window is when the work of addiction recovery is most accessible. It does not stay open indefinitely.
What the Evidence Shows
The strongest clinical data on ibogaine for addiction is for opioid dependence. Landmark work published in the American Journal of Drug and Alcohol Abuse documented that 12 of 20 participants showed no evidence of opioid withdrawal during ibogaine treatment — a pharmacological finding no other compound has replicated. Case series and observational studies have documented prolonged abstinence periods and reduced craving following single-session ibogaine treatment across multiple sites.
For alcohol dependence, the GDNF research is consistent. Animal data showing 90%+ reductions in voluntary alcohol consumption provided the mechanistic signal; human clinical data is thinner — small observational studies and case reports — but directionally consistent. The effect appears to hold for weeks to months when followed by structured integration.
The 2023 Stanford study published in Nature Medicine focused on PTSD and depression in 30 special operations veterans — not addiction — but confirmed the neuroplastic mechanism in a treatment-resistant population: 88% reduction in PTSD symptoms, 87% reduction in depression, 81% reduction in anxiety at one month. The limitations are genuine: 30 participants, no placebo arm, a single protocol. They should be stated alongside the numbers. They do not diminish what the numbers show in context.
Texas committed $50 million USD across UTMB, UTHealth Houston, Texas A&M, and Baylor to clinical ibogaine trials in 2023. Addiction-specific data at scale is forthcoming. The directional evidence that exists — across animal models, observational studies, and clinical case series — is consistent enough that treatment is not waiting for those results.
The Integration Window — and Why It Matters More Than Ceremony
The people who arrive at iboga ceremony with the strongest outcomes are often the ones who spent years trying everything else first. SSRIs that blunted rather than resolved. Abstinence-based programmes that held for months, then didn't. Therapy that circled without landing. By the time they arrive, they are not naive about the difficulty of what they are attempting. That earned scepticism — combined with the evidence that nothing else worked — tends to produce people who are genuinely ready to encounter what iboga shows them.
Iboga is not a cure for addiction. That sentence needs to be stated directly, because the research numbers — and the desperation of people who have found nothing else that works — create pressure to position it as one. What iboga produces is a neurological reset: a window during which craving is reduced, neuroplasticity is elevated, and new habits are more accessible than they were before. Noribogaine, ibogaine's active metabolite, remains pharmacologically active for weeks to months after ceremony — sustaining that window. What happens in it is determined entirely by what the person does with it.
Iboga ceremony followed by an immediate return to unchanged environments, relationships, and unaddressed triggers produces relapse. The MAPS summaries on ibogaine and chemical dependency document that outcomes diverge substantially based on what follows ceremony, not just what happens during it. The ceremony opens the door. Integration is the work of walking through it.
Integration coaching at Transcend runs $150–$300 CAD per session and is available remotely. For addiction specifically — where cues are embedded in workplaces, family gatherings, and social situations that are difficult or impossible to avoid — structured integration support in the weeks following ceremony is the factor that separates outcomes that hold from ones that don't.
What Iboga Does Not Do for Addiction
Iboga does not substitute for all the work of recovery. It surfaces unprocessed material — trauma, avoidance patterns, the emotional content the substance has been suppressing — but surfacing without processing can be disorienting rather than clarifying.
It does not produce lasting change in people who return to unchanged environments. Approximately 20–30% of people who complete ibogaine treatment do not experience significant reduction in craving or substance use. This is not a failure of the medicine — it reflects the range of individual responses and, in many cases, the absence of adequate integration support.
The experience does not accommodate avoidance. People who arrive expecting iboga to do the work for them encounter a medicine that shows them exactly what they have been avoiding — the material the substance was managing. That encounter is not comfortable. For many people, it is the first honest engagement they have had with what is actually driving the addiction. Whether they use that encounter productively depends on the preparation before ceremony and the integration that follows.
People seeking a shortcut — a way to skip the work of sustained change — are not appropriate candidates for iboga. This is the medicine for people who have been doing the work and are stuck, not for people who want to bypass the work entirely. The distinction tends to become clear quickly during the screening conversation.
Who Is Not an Appropriate Candidate
The contraindications for iboga are absolute. Several of them are common in addiction populations — which means the people who most urgently want this treatment are sometimes the ones least medically eligible for it. The complete contraindications guide covers every disqualifier. The most critical for addiction candidates:
- QT prolongation or significant cardiac arrhythmia. Ibogaine prolongs the QT interval. In someone with pre-existing prolongation, that additional effect can produce life-threatening arrhythmia. A 12-lead EKG is required before any ceremony date — not as a formality, but as the mechanism by which this risk is identified before it becomes a fatality. Providers who skip this step are not operating safely.
- SSRIs or SNRIs without a completed supervised taper. Ibogaine inhibits the serotonin transporter. Combining it with serotonergic medications creates conditions for serotonin syndrome, which can be fatal. No exception exists. SSRIs are commonly prescribed alongside addiction diagnoses — for co-occurring depression, anxiety, or PTSD — which means this contraindication affects a significant proportion of applicants. The taper must be supervised by a physician and confirmed complete before any ceremony date is set.
- Severe liver or kidney disease. Ibogaine is metabolised hepatically. Long-term alcohol use damages the liver — elevated AST and ALT beyond acceptable thresholds disqualify a candidate until those values normalise. In some cases they do not normalise. Liver disease is the contraindication most specific to alcohol-dependent candidates and the most commonly encountered in that population.
- Methadone without a supervised transition.Methadone has an extended half-life and complex interactions with ibogaine's opioid receptor mechanism. A managed transition to a shorter-acting opioid under physician supervision is required before ceremony — this process takes time and requires coordination between a prescribing physician and the ceremony provider.
- Active psychosis or schizophrenia-spectrum disorder. The experience amplifies what is present. Entering ceremony in a state of active psychosis does not produce stabilisation.
- Pregnancy.
Someone in acute psychiatric crisis is not an appropriate candidate at that time — regardless of how much they want access. Saying this clearly, without softening it, is part of what this work involves.
Is This Right for You?
If you have addiction history that has not responded to what has been available — and the medical contraindications above do not apply — the next step is an application. No ceremony date is confirmed before medical screening is complete: EKG, liver function panel, full blood panel, medication review, psychiatric history. Every application receives a personal response within 2–3 business days.
The screening conversation is where candidacy is determined. For some people that determination is a no — because of cardiac findings, liver values, or medications that cannot be safely resolved in a reasonable timeframe. We say it clearly. For others, it is a conversation about what preparation is required before proceeding.
More context is on the ceremony page, the FAQ, and the contraindications guide. Integration coaching is available remotely and can be arranged for people who have worked with other providers. If you have questions before applying, reach out directly at jake.nylund@gmail.com.